Celsus
Therapeutics Plc is no longer listed on any major stock exchanges and
is no longer publicly traded. The last available information about the
company dates back to 2018 when it was a clinical-stage
biopharmaceutical company focused on the development of treatments for
dermatological conditions.
At that time, the company's lead
product candidate was MRX-6, a topical treatment for psoriasis that
was in Phase 2 clinical trials. The company also had several other
product candidates in preclinical development for the treatment of
psoriasis, eczema, and other dermatological conditions.
However, it appears that the company has faced significant challenges
in its drug development efforts and financial position. In 2019, the
company entered into administration proceedings in the UK, which
typically involve the appointment of an independent administrator to
manage the company's affairs and assets in an effort to pay off
|